Differential regulation of somatodendritic serotonin 5-HT1A receptors by 2-week treatments with the selective agonists alnespirone (S-20499) and 8-hydroxy-2-(Di-n-propylamino)tetralin: microdialysis and autoradiographic studies in rat brain by Casanovas, Josep M. et al.
Differential Regulation of Somatodendritic Serotonin 5-HT1A
Receptors by 2-Week Treatments with the Selective
Agonists Alnespirone (S-20499) and
8-Hydroxy-2-(Di-n-Propylamino)tetralin: Microdialysis
and Autoradiographic Studies in Rat Brain
J. M. Casanovas, M. T. Vilaro´, G. Mengod, and F. Artigas
Department of Neurochemistry, Instituto de Investigaciones Biome´dicas de Barcelona, CSIC, Barcelona, Spain
Abstract: Single treatment with the serotonin (5-hydroxy-
tryptamine) 5-HT1A receptor agonists 8-hydroxy-2-(di-
n-propylamino)tetralin (8-OH-DPAT) and alnespirone
(S-20499) reduces the extracellular 5-HT concentration
(5-HText) in the rat midbrain and forebrain. Given the
therapeutic potential of selective 5-HT1A agonists in the
treatment of affective disorders, we have examined the
changes in 5-HT1A receptors induced by 2-week
minipump administration of alnespirone (0.3 and 3 mg/
kg/day) and 8-OH-DPAT (0.1 and 0.3 mg/kg/day). The
treatment with alnespirone did not modify baseline
5-HText but significantly attenuated the ability of 0.3
mg/kg s.c. alnespirone to reduce 5-HText in the dorsal
raphe nucleus (DRN) and frontal cortex. In contrast, the
ability of 8-OH-DPAT (0.025 and 0.1 mg/kg s.c.) to re-
duce 5-HText in both areas was unchanged by 8-OH-
DPAT pretreatment. Autoradiographic analysis revealed a
significant reduction of [3H]8-OH-DPAT and [3H]WAY-
100635 {3H-labeled N-[2-[4-(2-methoxyphenyl)-1-pipera-
zinyl]ethyl]-N-(2-pyridyl)cyclohexanecarboxamide z 3HCl}
binding to somatodendritic 5-HT1A receptors (but not to
postsynaptic 5-HT1A receptors) of rats pretreated with
alnespirone but not with 8-OH-DPAT. In situ hybridization
analysis revealed no change of the density of the mRNA
encoding the 5-HT1A receptors in the DRN after either
treatment. These data indicate that continuous treatment
for 2 weeks with alnespirone, but not with 8-OH-DPAT,
causes a functional desensitization of somatodendritic
5-HT1A receptors controlling 5-HT release in the DRN and
frontal cortex. Key Words: Serotonin 5-HT1A receptors—
5-Hydroxytryptamine release—Anxiety—Depression—Dor-
sal raphe nucleus—Frontal cortex.
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Serotonin (5-hydroxytryptamine) 5-HT1A receptor
agonists exhibit anxiolytic and/or antidepressant activity
in experimental models (for review, see De Vry, 1995),
and some members of the azapirone family, e.g., buspi-
rone and gepirone, are used in the treatment of affective
disorders (Pecknold, 1994). Alnespirone (S-20499) is an
aminochroman derivative with very high affinity for
5-HT1A receptors. Alnespirone shows anxiolytic and an-
tidepressant activity in animal models (Porsolt et al.,
1992; Barrett et al., 1994). It displays full agonistic
activity at somatodendritic 5-HT1A receptors and inhibits
forskolin-activated adenylate cyclase in hippocampal ho-
mogenates (Kidd et al., 1993). In keeping with its agonist
properties at presynaptic 5-HT1A receptors, it reduces the
5-HT turnover rate and 5-HT release in forebrain (Kidd
et al., 1993; Casanovas et al., 1997). Alnespirone is not
metabolized to 1-(2-pyrimidinyl)piperazine, a compound
that antagonizes a2-adrenoceptors (Bianchi et al., 1988),
and therefore it does not directly interact with catechol-
amine neurons (Dugast et al., 1998).
5-HT1A receptors are deeply involved in the control of
the activity of ascending serotonergic neurons. The ac-
tivation of somatodendritic 5-HT1A receptors inhibits the
firing activity of serotonergic neurons (Sprouse and
Aghajanian, 1986; Blier and de Montigny, 1987) and the
firing-dependent 5-HT release in projection areas (Sharp
et al., 1989). This reduction appears to take place pref-
erentially in forebrain areas innervated by serotonergic
neurons of the dorsal raphe nucleus (DRN) such as
frontal cortex or dorsal striatum (Casanovas and Artigas,
1996; Casanovas et al., 1997). Selective 5-HT reuptake
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inhibitors—behaving as indirect agonists at somatoden-
dritic 5-HT1A receptors—also inhibit 5-HT release with
the same regional pattern (Romero and Artigas, 1997).
5-HT1A receptors play a crucial role in the effects of
antidepressant drugs. Direct and indirect agonists of the
somatodendritic 5-HT1A receptors appear to induce re-
ceptor desensitization after chronic treatment, as mea-
sured by electrophysiological or neurochemical indexes
(Blier and de Montigny, 1987; Schechter et al., 1990; for
review, see Blier and de Montigny, 1994). This mecha-
nism is thought to be involved in the delayed action of
antidepressant drugs because chronic, but not acute,
treatment enhances the extracellular 5-HT concentration
(5-HText) in some forebrain areas (for review, see Arti-
gas et al., 1996). Hence, prevention of the 5-HT1A-based
negative feedback by concurrent administration of
5-HT1A receptor antagonists enhances the experimental
and clinical effects of selective 5-HT reuptake inhibitors
(Artigas et al., 1996; Pe´rez et al., 1997). However, the
desensitization of 5-HT1A receptors after chronic selec-
tive 5-HT reuptake inhibitor or 5-HT1A agonist treat-
ments has not been universally found (Bohmaker et al.,
1993; Sharp et al., 1993; Hjorth and Auerbach, 1994;
Invernizzi et al., 1995), a discrepancy for which no clear
explanations exist.
Given the potential usefulness of alnespirone for the
treatment of mood disorders, we have examined the
effects of its continuous administration for 2 weeks on
the density and function of 5-HT1A receptors using in
vivo microdialysis and receptor autoradiography. A par-
allel comparative study using the prototypic 5-HT1A
agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-
DPAT) has also been conducted.
MATERIALS AND METHODS
Animals
Male Wistar rats (Iffa Credo, Lyon, France) weighing 280–
320 g at the time of experiments were used. Animals were kept
in a controlled environment (12-h light–dark cycle and 22
6 2°C room temperature). Food and water were provided ad
libitum before and during the experiments. Animal care fol-
lowed the European Union regulations (O. J. of E. C. L358/1
18/12/1986).
Drugs and reagents
5-HT and 8-OH-DPAT were from Research Biochemicals
International (Natick, MA, U.S.A.). Alnespirone and citalo-
pram were kindly provided by the Institut de Recherches In-
ternationales Servier (Courbevoie, Paris) and Lundbeck A/S
(Valby, Copenhagen, Denmark), respectively. Other materials
and reagents were from local commercial sources.
Alnespirone and 8-OH-DPAT were administered with
minipumps. Two different doses of alnespirone (0.3 and 3
mg/kg/day) and 8-OH-DPAT (0.1 and 0.3 mg/kg/day) were
used. When administered as single subcutaneous doses, 3
mg/kg alnespirone and 0.3 mg/kg 8-OH-DPAT produced
equivalent (maximal) reductions of the 5-HT release in dorsal
striatium (Casanovas et al., 1997). Drugs were dissolved in
distilled water, and minipumps (Alzet 2002) were filled with
these solutions. Given the weight gain of the animals, the doses
used correspond to day 7 of treatment. Two different experi-
ments were conducted to test the effects of alnespirone and
8-OH-DPAT, respectively. In each, rats were randomly as-
signed to receive vehicle or the lower or the higher dose of each
drug. Control animals were implanted with minipumps filled
with distilled water. Minipumps were implanted subcutane-
ously with the animal under light ether anesthesia. Rats were
housed one per cage. One day before the microdialysis exper-
iments, minipumps were removed with the animal under pen-
tobarbital anesthesia (immediately before the implants of the
microdialysis probes; see below). The minipumps were cut
with an incisor blade, and it was checked that they were empty
by visual inspection.
To test the functional state of 5-HT1A receptors, challenge
doses of alnespirone (0.3 mg/kg s.c.) or 8-OH-DPAT were
administered after collection of baseline dialysate values to
groups of animals pretreated with saline or active drug. Given
the short half-life of 8-OH-DPAT, it was possible to administer
two different challenge doses (0.025 and 0.1 mg/kg s.c.) to each
rat in the same experiment. The effects of challenge doses of
the 5-HT1A agonists on 5-HT release were examined in the
DRN and frontal cortex of separate groups of rats treated with
either dose of alnespirone or 8-OH-DPAT and compared with
those produced in controls.
Surgery and microdialysis procedures
Microdialysis procedures were performed essentially as de-
scribed by Adell and Artigas (1991). Anesthetized rats (pento-
barbital, 60 mg/kg i.p.) were stereotaxically implanted with one
I-shaped probe in the DRN or frontal cortex. Coordinates [in
mm (Paxinos and Watson, 1986)] were taken from bregma and
dura mater and were as follows: AP 13.2, L 22.5, DV 26.0
for frontal cortex and AP 27.6, L 0.0 (the actual lateral
coordinate at the dura mater level was 23.1 mm), DV 27.5 for
DRN. In the latter area, microdialysis probes were implanted
with an angle of 30° to avoid obstruction of the cerebral
aqueduct. The length of membrane exposed to the brain tissue
was 4 mm (o.d. 5 0.25 mm) in frontal cortex and 1.5 mm in the
DRN. Animals were allowed to recover from surgery for ;20
h, and then probes were perfused with artificial CSF (125 mM
NaCl, 2.5 mM KCl, 1.26 mM CaCl2, and 1.18 mM MgCl2)
containing 1 mM citalopram at 0.25 ml/min. Sample collection
started 60 min after the beginning of perfusion. Dialysate
samples were collected every 20 min (5 ml). Usually five or six
fractions were collected before drug administration, of which
four were used to obtain the individual basal values. Challenge
doses of alnespirone and 8-OH-DPAT (first injection) were
administered around noon. At the end of the microdialysis
experiments, the animals were killed by decapitation, and the
brain was quickly removed and frozen (220°C) for further
autoradiographic and in situ hybridization analyses. The data
from animals with probes outside the limits of the brain struc-
tures of interest were not included in the calculations (typically
;15–20% of those implanted in the DRN).
Chromatographic analysis
5-HT was analyzed by a modification of an HPLC method
previously described (Adell and Artigas, 1991). The composi-
tion of HPLC eluent was as follows: 0.15 M NaH2PO4, 1.3 mM
octyl sodium sulfate, 0.2 mM EDTA (pH 2.8 adjusted with
phosphoric acid), and 27% methanol. 5-HT was separated in a
3-mm (partical size) ODS 2 column (7.5 3 0.46 cm; Beckman,
Fullerton, CA, U.S.A.) and detected amperometrically with a
Hewlett Packard model 1049 detector (oxidation potential, 0.6
V). Retention time was 3.5–4 min. The absolute detection limit
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for 5-HT was 0.5–1 fmol per sample. Dialysate 5-HT values
were calculated by reference to standard curves assayed daily.
Receptor autoradiography
Brain sections, 14 mm thick, were cut on a microtome-
cryostat (model HM 500M; Microm), thaw-mounted onto
3-aminopropyltriethoxysilane (Sigma)-treated slides, and kept
at 220°C until used. 3H-labeled WAY-100635 {N-[2-[4-(2-
methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridyl)cyclohex-
anecarboxamide z 3HCl} (80 Ci/mmol) and [3H]8-OH-DPAT
(234 Ci/mmol; Amersham, U.K.) were used as ligands. Opti-
mal preincubation time was determined in pilot experiments. In
brief, sections were preincubated for different times (0, 25, 40,
75, and 100 min) and processed as described below. A prein-
cubation time of 100 min was finally chosen (see Results).
Sections were preincubated for this time at room temperature in
170 mM Tris-HCl (pH 7.5), 4 mM CaCl2, and 0.01% ascorbic
acid and then incubated for 1 ([3H]8-OH-DPAT) or 2 h
([3H]WAY-100635) at room temperature in the same buffer
supplemented with 10 mM pargyline. Nonspecific binding was
defined in the presence of 10 mM 5-HT. In both cases, radio-
ligand concentration was 0.5 nM. Sections were washed twice
(5 min each) in the same buffer at 4°C, dipped in distilled water
at 4°C, and rapidly dried under cold air. Tissues were exposed
to Hyperfilm-3H (Amersham) together with plastic standards
(3H-Microscales; Amersham). Exposure time was 11 days for
[3H]8-OH-DPAT and 23 days for [3H]WAY-100635. Quanti-
tative analysis of the autoradiograms was performed with a
computerized image analysis system (MCID, St. Catharines,
Ontario, Canada). The autoradiographic analysis of sections of
representative animals of all experimental groups was per-
formed at once.
In situ hybridization histochemistry
An oligonucleotide probe complementary to the mRNA cod-
ing for the rat 5-HT1A receptor [amino acids 407–422 (Albert
et al., 1990)] was used. The oligonucleotide was 39 end-labeled
with terminal deoxynucleotidyltransferase (Boehringer Mann-
heim) and [a-32P]dATP (3,000 Ci/mmol; Du Pont New En-
gland Nuclear) obtaining a final specific activity of 0.7–1.2
3 104 Ci/mmol. Labeled probe was purified through NACS
PREPAC columns (BRL).
Before hybridization, frozen tissue sections were air-dried,
fixed for 20 min in 4% paraformaldehyde in phosphate-buff-
ered saline (1 3 PBS 5 2.6 mM KCl, 1.4 mM KH2PO4, 136
mM NaCl, and 8 mM Na2HPO4), washed once in 3 3 PBS and
twice in 1 3 PBS for 5 min each, and incubated in a freshly
prepared solution of predigested Pronase (Calbiochem) at a
final concentration of 24 U/ml in 50 mM Tris-HCl (pH 7.5) and
5 mM EDTA for 2 min at room temperature. Proteolytic activ-
ity was stopped by immersion for 30 s in 2 mg/ml glycine in
PBS. Tissues were rinsed in PBS and dehydrated through a
graded series of ethanol. For hybridization, labeled probes were
diluted to a final concentration of 2 3 107 cpm/ml in a solution
containing 50% formamide, 4 3 SSC (1 3 SSC 5 150 mM
NaCl and 15 mM sodium citrate), 13 Denhardt’s solution
(0.02% Ficoll, 0.02% polyvinylpyrrolidone, and 0.02% bovine
serum albumin), 10% dextran sulfate, 1% sarkosyl, 20 mM
phosphate buffer (pH 7.0), 250 mg/ml yeast tRNA, and 500
mg/ml salmon sperm DNA. Tissues were covered with 80 ml of
hybridization solution, overlaid with Nescofilm coverslips, and
incubated overnight in humid boxes at 42°C. Sections were
washed four times (45 min each) in 600 mM NaCl, 20 mM
Tris-HCl (pH 7.5), and 1 mM EDTA at 60°C, dehydrated in
graded ethanol solution, and dried. Hybridized sections were
exposed to b-Max film (Amersham) for 12 days at 270°C with
intensifying screens. Film optical densities over the region of
the DRN were measured with the MCID computerized image
analysis system.
Data and statistical analysis
Microdialysis results are expressed as femtomoles per frac-
tion (uncorrected for recovery) or as percentages of basal
values (individual means of four predrug fractions). Statistical
analysis (SPSS/PC1) of drug effects on dialysate 5-HT level
was performed using one- or two-way ANOVA for repeated
measures of raw data with dose or region as the independent
factor. ANOVA of areas under the curve (AUCs) or peak
reductions was also used to examine further the influence of
dose and region factors on the 5-HT output. Given the different
pharmacokinetics of both drugs, fractions 6–16 were used to
calculate the AUC values for alnespirone, and fractions 6–8
(0.025 mg/kg s.c.) and 14–16 (0.1 mg/kg s.c.) were used for the
two challenge doses of 8-OH-DPAT (Casanovas et al., 1997).
These fractions are those in which the effect of 0.025 mg/kg
8-OH-DPAT was maximal. For consistency, we used also three
fractions to assess the effects of 0.1 mg/kg 8-OH-DPAT, al-
though this dose elicited more lasting reductions of the 5-HT
output. The fraction immediately after the injection of drugs
was omitted owing to the elevations of 5-HText produced by the
injection stress (Adell et al., 1997; see below).
Data from radioligand autoradiography are given as femto-
moles of receptor per milligram of protein. Results from in situ
hybridization are expressed as film optical density. One-way
ANOVA has been used to assess the effects of the treatments
on 5-HT1A receptor density in autoradiographic studies. Data
are given as mean 6 SEM values. The number of animals in
each group is given in the figure legends. Statistical signifi-
cance has been set at the 95% confidence level (two-tailed).
RESULTS
Microdialysis experiments
Baseline dialysate 5-HT values in the presence of 1
mM citalopram were 52.7 6 3.2 and 17.5 6 0.7 fmol per
fraction in the DRN and frontal cortex, respectively (n
5 46 rats each). Overall, baseline 5-HT values were not
different in control and alnespirone-treated rats (Fig.
1A). A significant increment (F2,20 5 5.05, p , 0.02,
one-way ANOVA) was observed in the frontal cortex of
rats treated with 0.1 mg/kg/day 8-OH-DPAT compared
with controls, yet no such difference was found for those
treated with 0.3 mg/kg/day (Fig. 1B). Also, no differ-
ences in baseline 5-HT values were found in the DRN
after chronic treatment with 8-OH-DPAT or alnespirone.
A challenge dose of 0.3 mg/kg alnespirone reduced the
5-HT output to 45% of baseline in frontal cortex and to
54% of baseline in the DRN of control rats (Fig. 2). This
effect was significantly attenuated in both regions of rats
pretreated with alnespirone (significant effect of time,
F15,300 5 20.68, p , 0.001; time 3 treatment interaction,
F30,300 5 1.57, p , 0.035 in the DRN; significant effect
of time, F15,300 5 34.34, p , 0.001; time 3 treatment
interaction, F30,300 5 1.88, p , 0.005 in frontal cortex;
two-way repeated-measures ANOVA; Fig. 2). One-way
ANOVA of the AUCs revealed a significant effect of the
treatment (F2,20 5 8.26, p , 0.003 in DRN; F2,20 5 3.82,
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p , 0.04 in frontal cortex; Fig. 2). Post hoc Tukey’s test
revealed significant differences between control rats and
those treated with 3 mg/kg/day in both brain regions and
between controls and 0.3 mg/kg/day for the DRN. The
corresponding AUCs (expressed as percentages of pre-
drug values) were 62.1 6 4.0% for controls and 83.0
6 3.8% for 3 mg/kg/day alnespirone. A similar 20%
difference was noted in frontal cortex (55.0 6 3.5% in
controls vs. 75.0 6 6.9% in 3 mg/kg/day alnespirone).
Given the very short half-life of 8-OH-DPAT, it was
possible to administer two different challenge doses
(0.025 and 0.1 mg/kg; Fig. 3). Neither reduced the 5-HT
output differently in controls or 8-OH-DPAT-pretreated
rats, as judged from the maximal decrease elicited. The
AUCs corresponding to the three fractions with maximal
decrements (6–8 for 0.025 mg/kg; 14–16 for 0.1 mg/kg)
were also calculated. No significant attenuation of the
effect of 0.025 or 0.1 mg/kg 8-OH-DPAT was observed
in pretreated rats compared with controls (Fig. 3C and
D). In contrast, there was a tendency ( p 5 0.11) toward
a greater effect of 0.1 mg/kg 8-OH-DPAT in rats pre-
treated with 0.3 mg/kg/day.
Rats treated with 8-OH-DPAT had an increased
weight gain compared with controls over the 2-week
treatment period (87.1 6 2.6, 93.6 6 3.8, and 99.2
6 1.9 g for controls and 0.1 and 0.3 mg/kg/day 8-OH-
DPAT, respectively; F2,47 5 3.74, p , 0.035, one-way
ANOVA).
Radioligand autoradiography and in situ
hybridization
To assess whether the above differences were due to a
change in receptor number, we performed an autoradio-
graphic analysis of the brains of rats treated with both
5-HT1A agonists. To make sure that residual drug from
the challenge dose would not interfere with the binding
of the radioligands to 5-HT1A receptors, preliminary
experiments were conducted to determine the appropri-
ate preincubation time. Serial sections of a limited num-
ber of animals were preincubated for different intervals
(0–100 min) before incubation in the presence of [3H]8-
FIG. 1. Treatment with (A) alnespirone (ALN; 0.3 and 3 mg/kg/
day) or (B) 8-OH-DPAT (DPAT; 0.1 and 0.3 mg/kg/day) for 2
weeks did not induce consistent changes in the baseline dialy-
sate 5-HT values in frontal cortex (open columns) or DRN (filled
columns). *A significant increment was noted in frontal cortex of
the rats treated with 0.1 mg/kg/day 8-OH-DPAT (see text), but
this was not accompanied by a similar change at 0.3 mg/kg/day.
Data are mean 6 SEM (bars) values (n 5 7 or 8 rats per group).
FIG. 2. Effects of a challenge dose
of alnespirone (ALN; 0.3 mg/kg s.c.)
on 5-HT release in animals pre-
treated with vehicle (E) or 0.3 ()
or 3 (F) mg/kg/day ALN. A and
B: Effects in frontal cortex (FC)
and DRN, respectively. The eleva-
tion seen in the latter region is
caused by subcutaneous injection
of ALN. Two-way repeated-mea-
sures ANOVA revealed a significant
time 3 treatment interaction in both
areas. C: AUC of fractions 6–16
corresponding to both regions after
ALN treatment. Asterisks denote
significant differences versus con-
trols (by one-way ANOVA). Data are
mean 6 SEM (bars) values (n 5 7 or
8 rats per group).
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OH-DPAT. No apparent differences were noted between
rats treated with 8-OH-DPAT or alnespirone. As shown
in Fig. 4, specific binding increased in the DRN and
hippocampus with a preincubation time up to 100 min,
showing a plateau at 70–100 min. Therefore, this latter
time was chosen for both radioligands.
In agreement with the antagonistic character of WAY-
100635, the observed density of sites labeled by
[3H]WAY-100635 almost doubled that achieved with
[3H]8-OH-DPAT in all brain areas examined and for all
treatments. A similar or even higher ratio was observed
when total densities of binding sites (Bmax) were consid-
ered (data not shown). Three different measures of la-
beling density were performed in the DRN, correspond-
ing to the whole nucleus and its dorsal and ventral parts,
respectively. Also, densities of receptors were measured
in several postsynaptic areas, including the CA1 hip-
pocampal subfield (strata oriens and radiatum), the den-
tate gyrus, the interpeduncular nucleus, and the fronto-
parietal cortex. The labeling of pre- and postsynaptic
5-HT1A receptors in several of these areas by [3H]8-OH-
DPAT and [3H]WAY-100635 is shown, respectively, in
Figs. 5 and 6.
The treatment with alnespirone induced a dose-depen-
dent reduction of the labeling by [3H]8-OH-DPAT in the
DRN but not in postsynaptic areas (F2,17 5 6.35, p
, 0.01; F2,17 5 5.25, p , 0.02; and F2,17 55.75, p
, 0.02 in total DRN and its dorsal and ventral parts,
respectively; one-way ANOVA). Post hoc Tukey’s test
revealed a significant reduction of the tritium labeling
(;25–30%) between the control and 3 mg/kg/day al-
nespirone groups in all three instances (Fig. 7). The same
FIG. 3. Effects of two challenge
doses of 8-OH-DPAT (DPAT; 0.025
and 0.1 mg/kg s.c.) on 5-HT release
in animals pretreated with vehicle
(E) or 0.1 () or 0.3 (F) mg/kg/day
DPAT. A and B: Effects in frontal
cortex (FC) and DRN, respectively.
The elevation seen in the latter re-
gion is caused by the subcutane-
ous injection of DPAT. There were
no significant differences between
the effects of DPAT in control or
DPAT-pretreated rats. C and D:
AUCs of the periods of maximal re-
duction of 5-HT release after sub-
cutaneous administration of 0.025
and 0.1 mg/kg DPAT, respectively.
There was a nonsignificant effect
of the pretreatment (one-way
ANOVA). Data are mean 6 SEM
(bars) values (n 5 7 or 8 rats per
group).
FIG. 4. Effect of preincubation time on binding of [3H]8-OH-
DPAT to rat brain sections for the different experimental groups:
(A) in the hippocampal formation [HPC; area CA1 and dentate
gyrus (DG) (n 5 1)] and (B) in the DRN (n 5 2 or 3 rats per group).
No differences were noted between groups, and the plateau was
reached at 70–100 min in most cases, so the preincubation time
chosen to conduct the experiments was 100 min. ALN or Aln,
alnespirone.
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differences were noted when the tritiated 5-HT1A antag-
onist [3H]WAY-100635 was used to label 5-HT1A recep-
tors in adjacent sections. In this case, the corresponding
values were F2,17 5 5.67, p , 0.015; F2,17 5 4.11, p
, 0.035; and F2,17 5 6.20, p , 0.01 for the whole DRN
and its dorsal and ventral parts, respectively (one-way
ANOVA). No such differences were noted for postsyn-
aptic 5-HT1A receptors labeled with either radioligand
except for the CA1 field (stratum oriens), which showed
a significantly higher labeling in rats treated with 0.3
mg/kg/day alnespirone compared with controls. Also, the
labeling in the interpenduncular nucleus was higher in
rats treated with 3 mg/kg/day alnespirone than with 0.3
mg/kg/day (but not vs. controls).
In animals treated with 8-OH-DPAT, one-way
ANOVA revealed the existence of significant differences
in [3H]WAY-100635 binding to the DRN (F2,17 5 4.38,
p , 0.03 for the whole DRN; F2,17 5 5.97, p , 0.01 for
the ventral part), but post hoc Tukey’s test indicated that
these were due to a higher labeling in animals treated
with 0.3 mg/kg/day 8-OH-DPAT than in those treated
with 0.1 mg/kg/day (Fig. 8). No significant differences
were observed when 5-HT1A receptors were labeled with
[3H]8-OH-DPAT.
The specificity of the signal obtained with the oligo-
nucleotide probe used for in situ hybridization studies
has been previously demonstrated (Pompeiano et al.,
1992). On visual inspection of the autoradiograms, no
apparent differences in the intensity of the hybridization
signal for 5-HT1A receptor mRNA were observed be-
tween agonist- or vehicle-treated animals. In the region
of the DRN, where significant reductions in the densities
of 5-HT1A receptors had been observed, computer-as-
sisted measures of film optical densities were performed.
No significant difference was observed among the dif-
ferent treatment groups (Fig. 9). Thus, the optical density
values for control, low-dose, and high-dose groups were
0.23 6 0.01, 0.20 6 0.01, and 0.23 6 0.03 for alnespi-
rone and 0.23 6 0.01, 0.22 6 0.02, and 0.24 6 0.02 for
8-OH-DPAT, respectively (data from four to six rats per
group).
DISCUSSION
Although some evidence has been provided in vitro
(Albert et al., 1996), there is considerable debate about
the capacity of 5-HT1A agonists to desensitize/down-
regulate 5-HT1A receptors in vivo (for review, see De
Vry, 1995). With few exceptions (Welner et al., 1989;
Fanelli and McMonagle-Strucko, 1992), administration
of selective agents for 2–3 weeks did not result in a
reduced density of 5-HT1A sites in receptor binding or
autoradiographic studies. Functional measures of
5-HT1A receptor activity have also yielded conflicting
FIG. 5. Coronal sections show the autoradiographic labeling of 5-HT1A receptors by [3H]8-OH-DPAT at two different levels in brains of
rats treated for 2 weeks with (A) vehicle, (B) alnespirone (3 mg/kg/day), or (C) 8-OH-DPAT (0.3 mg/kg/day). CA1 (Or) and CA1 (Rad),
strata oriens and radiatum, respectively, of the CA1 hippocampal subfield; DG (Mol), dentate gyrus, stratum moleculare; IP, interpe-
duncular nucleus; DR, DRN. Note the decreased receptor density in the DRN of the rat treated with alnespirone (B2) compared with the
control rat (A2). Bar 5 3 mm.
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results. Using electrophysiological paradigms, Blier and
de Montigny (1987) found a decreased responsiveness of
somatodendritic 5-HT1A autoreceptors to the microion-
tophoretic application of 5-HT, 8-OH-DPAT, or gepi-
rone after a 2-week treatment with the latter agent using
minipumps. No such effect was observed when the chal-
lenge doses of 8-OH-DPAT or gepirone were systemi-
cally administered. Moreover, Schechter et al. (1990)
found no change in 5-HT1A pre- and postsynaptic recep-
tor density but a reduced sensitivity of somatodendritic
receptors as assessed electrophysiologically in vitro after
a 2-week administration of ipsapirone. However, to our
knowledge, no single study has so far demonstrated a
down-regulation or desensitization (as measured electro-
physiologically) of somatodendritic 5-HT1A receptors af-
ter treatment with 8-OH-DPAT for similar intervals.
Microdialysis studies are also controversial. Sharp et
al. (1993) failed to find a reduced sensitivity of 5-HT1A
receptors controlling 5-HT release after 2-week treat-
ments with 8-OH-DPAT (1 mg/kg s.c. twice daily),
buspirone (0.5 and 5 mg/kg s.c. twice daily), or ipsapi-
rone (5 mg/kg s.c. twice daily). In contrast, Kreiss and
Lucki (1992, 1997) reported desensitization of DRN
5-HT1A receptors after 7 and 14 days of treatment with 1
FIG. 6. Coronal sections show the autoradiographic labeling of 5-HT1A receptors by [3H]WAY-100635 at two different levels in brains
of rats treated for 2 weeks with (A) vehicle, (B) alnespirone (3 mg/kg/day), or (C) 8-OH-DPAT (0.3 mg/kg/day). CA1 (Or) and CA1 (Rad),
strata oriens and radiatum, respectively, of the CA1 hippocampal subfield; DG (Mol), dentate gyrus, stratum moleculare; IP, interpe-
duncular nucleus; DR, DRN. Note the decreased receptor density in the DRN of the rat treated with alnespirone (B2) compared with the
control rat (A2). Bar 5 3 mm.
FIG. 7. 5-HT1A receptor binding density in brains
of rats treated with alnespirone (ALN) as assessed
by quantitative autoradiography with [3H]8-OH-
DPAT (left panel) and [3H]WAY-100635 (right pan-
el). The numbers in the abscissa correspond to the
following areas: 1, DRN (whole nucleus); 2, DRN
(dorsal part); 3, DRN (ventral part); 4, CA1 (stratum
oriens); 5, CA1 (stratum radiatum); 6, dentate gyrus
(stratum moleculare); 7, subiculum; 8, interpedun-
cular nucleus; and 9, cingulate cortex. One-way
ANOVA revealed the existence of a significant
treatment factor for ALN in the DRN using both
ligands: *significant difference versus controls;
1significant difference versus the lower dose (by
post hoc Tukey’s test).
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mg/kg/day s.c. 8-OH-DPAT. Both studies were con-
ducted in chloral hydrate-anesthetized rats, and Kreiss
and Lucki (1992, 1997) used a larger challenge dose [1
mg/kg/ vs. 0.025 mg/kg s.c. in the study by Sharp et al.
(1993)]. The use of 1 mg/kg 8-OH-DPAT seems inap-
propriate to test the functional state of 5-HT1A receptors.
In our hands, the ED50 of 8-OH-DPAT to reduce 5-HT
release in the rat brain is 0.017 mg/kg s.c. (Casanovas et
al., 1997). At 1 mg/kg s.c. 8-OH-DPAT may interact
with other neuronal systems, e.g., the 5-HT transporter,
for which it displays a moderate affinity (Schoemaker
and Langer, 1986) or with the 5-HT7 receptor (Ruat et
al., 1993). Furthermore, in the studies by Kreiss and
Lucki (1992 1997), the reduction of striatal 5-HT release
elicited by 1 mg/kg 8-OH-DPAT was severalfold less
marked and had a slower time course than that observed
in other studies, even using doses 10–60 times lower
(Sharp et al., 1993; Casanovas et al., 1997). This dis-
crepancy may perhaps be accounted for by methodolog-
ical differences, such as a different analytical method or
a different contribution of nonneuronal 5-HT pools, e.g.,
platelets, to dialysate 5-HT. Indeed, the marked reduc-
tion of 5-HT release observed after low 8-OH-DPAT
doses in the present and previous studies from this lab-
oratory (Adell et al., 1993; Casanovas et al., 1997) sup-
ports a neuronal origin of the 5-HT detected in DRN and
forebrain dialysates in our experimental conditions.
The present study indicates that a 2-week treatment
with alnespirone attenuates the ability of a further
challenge dose to reduce 5-HT release in the somato-
dendritic and terminal regions of DRN neurons. This
effect is likely accounted for by the parallel dose-
dependent reduction of the density of somatodendritic
5-HT1A receptors. Contrary to what could be expected
from the full agonistic character of 8-OH-DPAT, the
continuous treatment with this agent did not reduce the
density of somatodendritic or postsynaptic 5-HT1A
receptors after treatment for the same interval. The
inability of 8-OH-DPAT to desensitize/down-regulate
5-HT1A receptors cannot be explained by pharmaco-
kinetic reasons, i.e., both drugs were given by
minipumps to ensure a sustained occupation of
5-HT1A receptors, or by an insufficient dose of 8-OH-
DPAT. The ED50 values of alnespirone and 8-OH-
DPAT to reduce the 5-HT release (peak effect) are
0.19 and 0.017 mg/kg s.c, respectively (Casanovas et
al., 1997). Maximal reductions of 5-HT release in
dorsal striatum or frontal cortex after single treatment
were achieved with 3 mg/kg s.c. alnespirone and 0.3
mg/kg s.c. 8-OH-DPAT. These doses, which were the
maximal daily doses used in the present study, repre-
sent 16 times the ED50 for alnespirone and 18 times
the ED50 for 8-OH-DPAT. Therefore, they should be
considered equivalent in terms of the activation of
FIG. 8. 5-HT1A receptor binding density in brains
of rats treated with 8-OH-DPAT as assessed by
quantitative autoradiography with [3H]8-OH-DPAT
(left panel) and [3H]WAY-100635 (right panel).
The numbers in the abscissa correspond to the
following areas: 1, DRN (whole nucleus); 2, DRN
(dorsal part); 3, DRN (ventral part); 4, CA1 (stratum
oriens); 5, CA1 (stratum radiatum); 6, dentate gyrus
(stratum moleculare); 7, subiculum; 8, interpedun-
cular nucleus; and 9, cingulate cortex. *Significant
difference versus controls; 1Significant difference
versus the lower dose (by post hoc Tukey’s test).
FIG. 9. Coronal sections show the distribution of 5-HT1A receptor mRNA in the DRN (DR) of rats treated for 2 weeks with (A) vehicle,
(B) alnespirone (3 mg/kg/day), or (C) 8-OH-DPAT (0.3 mg/kg/day). Sections are from the same animals shown in Figs. 5 and 6. Bar 5
3 mm.
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5-HT1A receptors controlling 5-HT release. Because
no data are available on the receptor reserve for al-
nespirone in the DRN, it is unclear whether the above
doses are also equivalent in terms of receptor occu-
pancy. In any case, it appears that the daily doses of
8-OH-DPAT used were sufficient to activate somato-
dendritic 5-HT1A receptors as treated rats displayed a
dose-dependent weight gain increase, an effect that
may be attributed to the hyperphagic action of 8-OH-
DPAT (Hutson et al., 1986).
The down-regulation of 5-HT1A receptor density ob-
served in the DRN after chronic alnespirone treatment
was not paralleled by a decrease of 5-HT1A receptor
mRNA abundance in this nucleus. This fact suggests that
the regulatory events leading to long-term decreased
numbers of receptors do not involve reduced levels of
gene transcription, but are more likely to take place at the
level of the receptor protein synthesis and/or degrada-
tion. Although in several neurotransmitter systems short-
term agonist-induced down-regulation of receptor num-
ber is often accompanied by decreased levels of receptor
mRNA (for review, see Collins et al., 1991), a situation
similar to the one found in the present study has also
been reported. Thus, agonist exposure for 72 h of choroid
plexus epithelial cells results in loss of 5-HT2C receptor
binding sites without alterations in the levels of 5-HT2C
receptor mRNA (Barker and Sanders-Bush, 1993). We
are not aware, however, of any study addressing the
effect of prolonged (weeks) 5-HT agonist treatment on
the levels of both receptor number and mRNA abun-
dance.
The unchanged density/efficacy of postsynaptic
5-HT1A receptors after sustained alnespirone and 8-OH-
DPAT administration is also common to other 5-HT1A
agonists (Blier and de Montigny, 1987; Schechter et al.,
1990; Fanelli and McMonagle-Strucko, 1992; for re-
view, see De Vry, 1995) and may be ascribed to the
different characteristics of pre- and postsynaptic 5-HT1A
receptors. Thus, they appear to be identical from molec-
ular and biochemical points of view (Albert et al., 1990;
Radja et al., 1992). However, whereas postsynaptic hip-
pocampal 5-HT1A receptors are negatively coupled to
adenylyl cyclase (De Vivo and Maayani, 1986) and to a
potassium channel via pertussis toxin-sensitive G pro-
teins (Andrade et al., 1986), only the latter effector
system appears to be present in DRN (Clarke et al.,
1996). Differences in the ability to evoke an agonistic
response have also been reported, with selective 5-HT1A
agonists displaying a higher agonistic character at DRN
receptors compared with hippocampus (Sprouse and
Aghajanian, 1988). Finally, the larger receptor reserve in
the DRN (Meller et al., 1990; Cox et al., 1993) may also
be accountable. Hence, the sustained interaction of se-
lective agonists with 5-HT1A receptors may result in a
differential regulation of the protein at pre- and postsyn-
aptic sites.
However, despite these differences, it seemed sur-
prising that alnespirone down-regulated 5-HT1A re-
ceptors in the DRN, whereas 8-OH-DPAT did not. In
a striking similarity with the present results, Bohm-
aker et al. (1993) reported the lack of desensitization
of the 5-HT1A receptors controlling 5-HT synthesis
after a 2-week treatment with 8-OH-DPAT (either
twice daily or with minipumps; 0.4 and 4 mg/kg/day).
In contrast, the treatment with gepirone or ipsapirone
reduced the ability of a further challenge dose to
reduce 5-HT synthesis. The interpretation of these
differences is difficult, because all these agents behave
as full agonists at somatodendritic 5-HT1A receptors
and suppress the serotonergic cell firing rate (Sprouse
and Aghajanian, 1988; Kidd et al., 1993). Nonetheless,
behavioral differences between selective 5-HT1A ago-
nists have been reported (Scott et al., 1994). Bohmaker
et al. (1993) speculated that the differences between
8-OH-DPAT and azapirones after chronic treatment
might be due to a complex control of serotonergic
neurons by pre-and postsynaptic 5-HT1A receptors.
Evidence for this possibility comes from electrophys-
iological (Blier and de Montigny, 1987) and neuro-
chemical (Romero et al., 1994) studies. Under this
assumption, the effects of a challenge dose of alnespi-
rone on 5-HT release would be mainly due to the
activation of somatodendritic receptors, whereas those
of 8-OH-DPAT would also involve postsynaptic
5-HT1A receptors because the latter agent is consid-
ered to have a greater agonist character at postsynaptic
sites (Sprouse and Aghajanian, 1988). However, the
data of the present study do not support these argu-
ments (Bohmaker et al., 1993) because no consistent
changes in density in postsynaptic areas were ob-
served after 8-OH-DPAT treatment.
In summary, the present data support the proposal that
the ability of a challenge dose of alnespirone to reduce
5-HT release is diminished by a 2-week pretreatment.
This is most likely accounted for by a reduction of the
density of somatodendritic 5-HT1A receptors, as indi-
cated by autoradiographic experiments. The failure of
8-OH-DPAT to desensitize/down-regulate 5-HT1A re-
ceptors at doses equivalent in terms of the activation of
5-HT1A receptors controlling 5-HT release is unclear and
deserves further investigation.
Acknowledgment: Work supported by grants from the In-
stitut de Recherches Internationales Servier, the Fondo de In-
vestigacio´n Sanitaria (grant 98/0697), and the CICYT (grant
SAF96-0336). We acknowledge the skillful technical assis-
tance of Leticia Campa. Thanks are given to the pharmaceutical
companies for their kind supply of drugs.
REFERENCES
Adell A. and Artigas F. (1991) Differential effects of clomipramine
given locally or systemically on extracellular 5-hydroxytrypta-
mine in raphe nuclei and frontal cortex. An in vivo microdialysis
study. Naunyn Schmiedebergs Arch. Pharmacol. 343, 237–244.
Adell A., Carceller A., and Artigas F. (1993) In vivo brain dialysis
study of the somatodendritic release of serotonin in the raphe
nuclei of the rat: effects of 8-hydroxy-2-(di-n-propylamino)tetra-
lin. J. Neurochem. 60, 1673–1681.
J. Neurochem., Vol. 72, No. 1, 1999
270 J. M. CASANOVAS ET AL.
Adell A., Casanovas J. M., and Artigas F. (1997) Comparative study in
the rat of the actions of different types of stress on the release of
5-HT in raphe nuclei and forebrain areas. Neuropharmacology 36,
735–741.
Albert P. R., Zhou Q. Y., Van Tol H. H. M., Bunzow J. R., and Civelli
O. (1990) Cloning, functional expression and messenger RNA
tissue distribution of the rat 5-hydroxytryptamine1A receptor gene.
J. Biol. Chem. 265, 5825–5832.
Albert P. R., Lembo P., Storring J. M., Charest A., and Saucier C.
(1996) The 5-HT1A receptor: signaling, desensitization, and gene
transcription. Neuropsychopharmacology 14, 19–25.
Andrade R., Malenka R. C., and Nicoll R. A. (1986) A G protein
couples serotonin and GABAB receptors to the same channel in
hippocampus. Science 234, 1261–1265.
Artigas F., Romero L., de Montigny C., and Blier P. (1996) Acceler-
ation of the effect of selected antidepressant drugs in major
depression by 5-HT1A antagonists. Trends Neurosci. 19, 378–383.
Barker E. L. and Sanders-Bush E. (1993) 5-Hydroxytrypamine1C re-
ceptor density and mRNA levels in choroid plexus epithelial cells
after treatment with mianserin and (2)-1-(4-bromo-2,5-dime-
thoxyphenyl)-2-aminopropane. Mol. Pharmacol. 44, 725–730.
Barrett J. E., Gamble E. H., Zhang L., and Guardiola-Lemaitre B.
(1994) Anticonflict and discriminative stimulus effects in the
pigeon of a new methoxy-chroman 5-HT(1A) agonist, (1)S 20244
and its enantiomers (1)S 20499 and (2)S 20500. Psychopharma-
cology (Berl.) 116, 73–78.
Bianchi G., Caccia S., Della Vedova F., and Garattini S. (1988) The
alpha 2-adrenoceptor antagonist activity of ipsapirone and gepi-
rone is mediated by their common metabolite 1-(2-pyrimidinyl)-
piperazine (PmP). Eur. J. Pharmacol. 151, 365–371.
Blier P. and de Montigny C. (1987) Modification of 5-HT neuron
properties by sustained administration of the 5-HT1A agonist gepi-
rone: electrophysiological studies in the rat brain. Synapse 1,
470–480.
Blier P. and de Montigny C. (1994) Current advances and trends in the
treatment of depression. Trends Pharmacol. Sci. 15, 220–226.
Bohmaker K., Eison A. S., Yocca F. D., and Meller E. (1993) Com-
parative effects of chronic 8-OH-DPAT, gepirone and its ipsapi-
rone treatment on the sensitivity of somatodendritic 5-HT1A au-
toreceptors. Neuropharmacology 32, 527–534.
Casanovas J. M. and Artigas F. (1996) Differential effects of ipsapirone
on 5-HT release in the dorsal and median raphe neuronal path-
ways. J. Neurochem. 67, 1945–1952.
Casanovas J. M., Le´sourd M., and Artigas F. (1997) The effect of the
selective 5-HT1A agonists alnespirone (S-20499) and 8-OH-DPAT
on extracellular 5-hydroxytryptamine in different regions of rat
brain. Br. J. Pharmacol. 122, 733–741.
Clarke W. P., Yocca F. D., and Maayani S. (1996) Lack of 5-hydroxy-
tryptamine (1A)-mediated inhibition of adenylyl cyclase in dorsal
raphe of male and female rats. J. Pharmacol. Exp. Ther. 277,
1259–1266.
Collins S., Caron M. G., and Lefkowitz R. L. (1991) Regulation of
adrenergic receptor responsiveness through modulation of recep-
tor gene expression. Annu. Rev. Physiol. 53, 497–508.
Cox R. F., Meller E., and Waszczak B. L. (1993) Electrophysiological
evidence for a large receptor reserve for inhibition of dorsal raphe
neuronal firing by 5-HT(1A) agonists. Synapse 14, 297–304.
De Vivo M. and Maayani S. (1986) Characterization of the
5-hydroxytryptamine1A receptor-mediated inhibition of forskolin-
stimulated adenylate cyclase activity in guinea pig and rat hip-
pocampal membranes. J. Pharmacol. Exp. Ther. 238, 248–253.
De Vry J. (1995) 5-HT1A receptor agonists: recent developments and
controversial issues. Psychopharmacology (Berl.) 121, 1–26.
Dugast C., Soulie`re F., Schmitt P., Casanovas J. M., Fattaccini C. M.,
Mocae¨r E., Le´sourd M., Renaud B., Artigas F., Hamon M., and
Chouvet G. (1998) Is the potent 5-HT1A receptor agonist, alnespi-
rone (S-20499), affecting dopaminergic systems in the rat brain?
Eur. J. Pharmacol. 350, 171–180.
Fanelli R. J. and McMonagle-Strucko K. (1992) Alteration of 5-HT1A
receptor binding sites following chronic treatment with ipsapirone
measured by quantitative autoradiography. Synapse 12, 75–81.
Hjorth S. and Auerbach S. B. (1994) Lack of 5-HT(1A) autoreceptor
desensitization following chronic citalopram treatment, as deter-
mined by in vivo microdialysis. Neuropharmacology 33, 331–334.
Hutson P. H., Dourish C. T., and Curzon G. (1986) Neurochemical and
behavioural evidence for mediation of the hyperphagic action of
8-OH-DPAT by 5-HT cell body autoreceptors. Eur. J. Pharmacol.
129, 347–352.
Invernizzi R., Bramante M., and Samanin R. (1995) Extracellular
concentrations of serotonin in the dorsal hippocampus after acute
and chronic treatment with citalopram. Brain Res. 696, 62–66.
Kidd E. J., Hajdahmane S., Jolas T., Lanfumey L., Fattaccini C. M.,
Guardiola-Lemaitre B., Gozlan H., and Hamon M. (1993) New
methoxy-chroman derivatives, 4(N-(5-methoxy-chroman-3-yl)
N-propylamino)butyl-8-azaspiro-(4,5)-decane-7,9-dione [(1/2)S
20244] and its enantiomers, (1)S 20499 and (2)S 20500, with
potent agonist properties at central 5-hydroxytryptamine1A recep-
tors. J. Pharmacol. Exp. Ther. 264, 863–872.
Kreiss D. S. and Lucki I. (1992) Densensitization of 5-HT1A autore-
ceptors by chronic administration of 8-OH-DPAT. Neuropharma-
cology 31, 1073–1076.
Kreiss D. S. and Lucki I. (1997) Chronic administration of the 5-HT1A
receptor agonist 8-OH-DPAT differentially desensitizes 5-HT1A
autoreceptors of the dorsal and median raphe nucleus. Synapse 25,
107–116.
Meller E., Goldstein M., and Bohmaker K. (1990) Receptor reserve for
5-hydroxytryptamine-mediated inhibition of serotonin synthesis: a
possible relationship to anxiolytic properties of 5-hydroxytrypta-
mine agonists. Mol. Pharmacol. 37, 231–237.
Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coor-
dinates. Academic Press, Sydney.
Pecknold J. C. (1994) Serotonin 5-HT1A agonists—a comparative
review. CNS Drugs 2, 234–251.
Pe´rez V., Gilaberte I., Faries D., Alvarez E., and Artigas F. (1997)
Randomised, double-blind, placebo-controlled trial of pindolol in
combination with fluoxetine antidepressant treatment. Lancet 349,
1594–1597.
Pompeiano M., Palacios J. M., and Mengod G. (1992) Distribution and
cellular localization of mRNA coding for 5-HT1A receptor in the
rat brain: correlation with receptor binding. J. Neurosci. 12, 440–
453.
Porsolt R. D., Lenegre A., Caignard D. H., Pfeiffer B., Mocaer E., and
Guardiola-Lemaitre B. (1992). Psychopharmacological profile of
a new chroman derivative with 5-HT1A agonist properties S 20499
(1). Drug Dev. Res. 27, 389–402.
Radja F., Daval G., Hamon M., and Verge´ D. (1992) Pharmacological
and physicochemical properties of pre- versus postsynaptic
5-hydroxytryptamine1A receptor binding sites in the rat brain: a
quantitative autoradiographic study. J. Neurochem. 58, 1338–
1346.
Romero L. and Artigas F. (1997) Preferential potentiation of the effects
of serotonin uptake inhibitors by 5-HT1A receptor antagonists in
the dorsal raphe pathway. Role of somatodendritic autoreceptors.
J. Neurochem. 68, 2593–2603.
Romero L., Celada P., and Artigas F. (1994) Reduction of in vivo
striatal 5-hydroxytryptamine release by 8-OH-DPAT after inacti-
vation of Gi/Go proteins in dorsal raphe nucleus. Eur. J. Phar-
macol. 265, 103–106.
Ruat M., Traiffort E., Leurs R., Tardivel-Lacombe J., Diaz J., Arrang
J. M., and Schwartz J. C. (1993) Molecular cloning, characteriza-
tion, and localization of a high-affinity serotonin receptor (5-HT7)
activating cAMP formation. Proc. Natl. Acad. Sci. USA 90, 8547–
8551.
Schechter L. E., Bolanos F. J., Gozlan H., Lanfumey L., Haj-Dahmane
S., Laporte A. M., Fattaccini C. M., and Hamon M. (1990)
Alterations of central serotoninergic and dopaminergic neuro-
transmission in rats chronically treated with ipsapirone: biochem-
ical and electrophysiological studies. J. Pharmacol. Exp. Ther.
255, 1335–1347.
Schoemaker H. and Langer S. Z. (1986) [3H]8-OH-DPAT labels the
serotonin transporter in the rat striatum. Eur. J. Pharmacol. 124,
371–373.
J. Neurochem., Vol. 72, No. 1, 1999
271CHRONIC EFFECTS OF 5-HT1A RECEPTOR AGONISTS
Scott P. A., Chou J. M., Tang H., and Frazer A. (1994) Differential
induction of 5-HT1A mediated responses in vivo by three chemically
dissimilar 5-HT1A agonists. J. Pharmacol. Exp. Ther. 270, 198–208.
Sharp T., Bramwell S. R., and Grahame-Smith D. G. (1989) 5-HT1
agonists reduce 5-hydroxytryptamine release in rat hippocampus
in vivo as determined by brain microdialysis. Br. J. Pharmacol.
96, 283–290.
Sharp T., McQuade R., Bramwell S., and Hjorth S. (1993) Effect of
acute and repeated administration of 5-HT1A receptor agonists on
5-HT release in rat brain in vivo. Naunyn Schmiedebergs Arch.
Pharmacol. 348, 339–346.
Sprouse J. S. and Aghajanian G. K. (1986) (2)-Propranolol blocks the
inhibition of serotonergic dorsal raphe cell firing by 5-HT1A
selective agonists. Eur. J. Pharmacol. 128, 295–298.
Sprouse J. S. and Aghajanian G. K. (1988) Responses of hippocampal
pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists:
a comparative study with dorsal raphe neurons. Neuropharmacol-
ogy 27, 707–715.
Welner S. A., de Montigny C., Descoches J., Desjardins P., and
Suranyi-Cadotte B. E. (1989) Autoradiographic quantification of
serotonin1A receptors in rat brain following antidepressant drug
treatment. Synapse 4, 347–352.
J. Neurochem., Vol. 72, No. 1, 1999
272 J. M. CASANOVAS ET AL.
